Basic Materials
Novozymes A/S(NVZMF)
Live Price
Offline$58.29
+0.00% today
1Y Change
-13.20%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $24.92B
- Revenue Growth
- -85.5%
- EPS Growth
- +86.6%
- Dividend Yield
- 1.6%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novozymes A/S (NVZMF) is a Basic Materials stock with a market cap of $24.92B and listed on OTC. The stock last traded around $58.29 and down 13.2% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -85.5%, EPS growth of +86.6%, a dividend yield of 1.6%. What stands out right now is revenue -85.5%, EPS +86.6%, free cash flow +13.7% with operating margin 21.2% and ROIC 2.6%. The dividend is present but secondary, with a yield around 1.6%. Valuation already assumes a fairly strong business story at P/E 38.0 and price/sales 6.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NVZMF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Basic Materials peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-85.5% vs 0.0% peer median
Operating Margin
Above sector median
+21.2% vs +10.5% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -85.5% and EPS is at +86.6%, with operating margin around 21.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -5.4% | -2.4% | -9.2% |
2026 Feb 25, 2026 | -33.1% | -1.0% | +3.2% | -4.1% |
2025 Aug 21, 2025 | -49.7% | +1.6% | +1.3% | -0.1% |
Benchmark Edge
NVZMF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NVZMF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NVZMF Max Drawdown
-28.22%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NVZMF and SPY.
Company Overview
Novozymes A/S
Other OTC
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
- Leadership
- Ester Baiget
- IPO Date
- Oct 15, 2010
- Employees
- 10.6k
- Street Address
- Krogshoejvej 36
- Mailing
- Bagsvaerd, 2880
- Region
- Bagsvaerd, DK
- Reporting Currency
- USD
- Investor Line
- 45 44 46 00 00
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 38.0
- EV/EBITDA
- 33.9
- Price/Sales
- 6.0
- Price/Book
- 2.0
Growth
- Revenue
- -85.5%
- EPS
- +86.6%
- Free Cash Flow
- +13.7%
Profitability
- Gross Margin
- 53.9%
- Operating Margin
- 21.2%
- Net Margin
- 14.0%
- ROE
- 5.4%
- ROIC
- 2.6%
Balance Sheet
- Debt/Equity
- 2.07
- Current Ratio
- 0.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.